Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Long GV, Nair N, Marbach D, Scolyer RA, Wilson S, Cotting D, Staedler N, Amaria RN, Ascierto PA, Tarhini AA, Robert C, Hamid O, Gaudy-Marqueste C, Lebbe C, Munoz-Couselo E, Menzies AM, Pages C, Curigliano G, Mandala M, Jessop N, Bader U, Perdicchio M, Teichgräber V, Muecke M, Markert C, Blank C

Open source

DOI: 10.1038/s41591-025-03967-2
Published: 2025 Nov
Container: Nature medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-025-03967-2,
  title = {Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.},
  author = {Long GV and Nair N and Marbach D and Scolyer RA and Wilson S and Cotting D and Staedler N and Amaria RN and Ascierto PA and Tarhini AA and Robert C and Hamid O and Gaudy-Marqueste C and Lebbe C and Munoz-Couselo E and Menzies AM and Pages C and Curigliano G and Mandala M and Jessop N and Bader U and Perdicchio M and Teichgräber V and Muecke M and Markert C and Blank C},
  year = {2025},
  journal = {Nature medicine},
  doi = {10.1038/s41591-025-03967-2},
  url = {https://doi.org/10.1038/s41591-025-03967-2}
}

RIS

TY  - JOUR
TI  - Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.
AU  - Long GV
AU  - Nair N
AU  - Marbach D
AU  - Scolyer RA
AU  - Wilson S
AU  - Cotting D
AU  - Staedler N
AU  - Amaria RN
AU  - Ascierto PA
AU  - Tarhini AA
AU  - Robert C
AU  - Hamid O
AU  - Gaudy-Marqueste C
AU  - Lebbe C
AU  - Munoz-Couselo E
AU  - Menzies AM
AU  - Pages C
AU  - Curigliano G
AU  - Mandala M
AU  - Jessop N
AU  - Bader U
AU  - Perdicchio M
AU  - Teichgräber V
AU  - Muecke M
AU  - Markert C
AU  - Blank C
PY  - 2025
JO  - Nature medicine
DO  - 10.1038/s41591-025-03967-2
UR  - https://doi.org/10.1038/s41591-025-03967-2
ER  -

APA

GV, L., N, N., D, M., RA, S., S, W., D, C., N, S., RN, A., PA, A., AA, T., C, R., O, H., C, G., C, L., E, M., AM, M., C, P., G, C., M, M., N, J., U, B., M, P., V, T., M, M., C, M., & C, B. (2025). Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.. Nature medicine. https://doi.org/10.1038/s41591-025-03967-2

Source records

pubmed · retrieved 2026-09-25T22:44:56.014Z